[18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [18F]FDOPA and [11C]DASB PET study in Parkinson's disease

被引:42
|
作者
Pavese, N. [1 ]
Simpson, B. S. [1 ]
Metta, V. [2 ,3 ,4 ]
Ramlackhansingh, A. [1 ]
Chaudhuri, K. Ray [2 ,3 ,4 ]
Brooks, D. J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Neurosci, London, England
[2] Kings Coll London, Natl Parkinson Fdn, Ctr Excellence, London WC2R 2LS, England
[3] Lewisham Hosp NHS Trust, London, England
[4] Kings Coll London, Biomed Res Ctr, London WC2R 2LS, England
基金
英国医学研究理事会;
关键词
Positron emission tomography (PET); F-18]FDOPA; C-11]DASB serotonin Parkinson; Monoamine; Extrastriatal; F-18-DOPA PET; I-123-BETA-CIT SPECT; CONTAINING NEURONS; FLUORODOPA UPTAKE; F-18; FLUORODOPA; MIDBRAIN; DOPAMINE; BINDING; DORSAL; BRAIN;
D O I
10.1016/j.neuroimage.2011.09.034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Brain uptake of [F-18]FDOPA, measured with PET, reflects the activity of aromatic amino acid decarboxylase, an enzyme largely expressed in monoaminergic nerve terminals. This enzyme catalyzes a number of decarboxylation reactions including conversion of L-dopa into dopamine and 5-hydroxytryptophan into serotonin. For more than 20 years [F-18]FDOPA PET has been used to assess dopaminergic nigrostriatal dysfunction in patients with Parkinson's disease (PD). More recently, however, [F-18]FDOPA PET has also been employed as a marker of serotoninergic and noradrenergic function in PD patients. In this study, we provide further evidence in support of the view that [F-18]FDOPA PET can be used to evaluate the distribution and the function of serotoninergic systems in the brain. Eighteen patients with PD were investigated with both [F-18]FDOPA and [C-11]DASB PET, the latter being a marker of serotonin transport (SERT) availability. We then assessed the relationship between measurements of the two tracers within brain serotoninergic structures. [F-18]FDOPA uptake in the median raphe nuclei complex of PD patients was significantly correlated with SERT availability in the same structure. Trends towards significant correlations between [F-18]FDOPA Ki values and [C-11]DASB binding values were also observed in the hypothalamus and the anterior cingulate cortex, suggesting a serotoninergic contribution to [F-18]FDOPA uptake in these regions. Conversely, no correlations were found in brain structures with mixed dopaminergic, serotoninergic and noradrenergic innervations, or with predominant dopaminergic innervation. These findings provide evidence that [F-18]FDOPA PET represents a valid marker of raphe serotoninergic function in PD and supports previous studies where [F-18]FDOPA PET has been used to assess serotoninergic function in PD. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1080 / 1084
页数:5
相关论文
共 50 条
  • [1] Noradrenergic mechanisms in Parkinson's disease, studied with [18F]FDOPA and [11C]MeNER PET
    Kinnerup, M.
    Sommerauer, M.
    Ostergaard, K.
    Borghammer, P.
    Gjedde, A.
    Nahimi, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 47 - 48
  • [2] [18F]FDOPA PET as an endophenotype for Parkinson's disease linkage studies
    Racette, BA
    Good, L
    Antenor, JA
    McGee-Minnich, L
    Moerlein, SM
    Videen, TO
    Perlmutter, JS
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2006, 141B (03) : 245 - 249
  • [3] 11C and 18F PET radioligands for the serotonin transporter (SERT)
    Stehouwer, Jeffrey S.
    Goodman, Mark M.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 (3-4): : 114 - 119
  • [4] Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP)
    Ambrosini, V.
    Morigi, J. J.
    Nanni, C.
    Castellucci, P.
    Fanti, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (01): : 58 - 69
  • [5] [18F]FDOPA PET and clinical features in a Parkinson's disease patient with manganese exposure
    Racette, BA
    Antenor, J
    Kotagal, V
    Videen, T
    Moerlein, S
    Goldman, J
    MOVEMENT DISORDERS, 2002, 17 : S108 - S108
  • [6] The impact of dopamine on aggression: An [18F]FDOPA PET study
    Vernaleken, Ingo
    Schlueter, Thorben
    Dautzenberg, Kai
    Schmaljohann, Joern
    Winz, Oliver
    Mottaghy, Felix
    Gruender, Gerhard
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [7] [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease
    Rinne, JO
    Nurmi, E
    Ruottinen, HM
    Bergman, J
    Eskola, O
    Solin, O
    SYNAPSE, 2001, 40 (03) : 193 - 200
  • [8] Neuroticism Polygenic Association Score and Dopaminergic Systems Correlates: Investigations With [18F]-FDOPA, [11C] NNC-112, and [18F]Fallypride PET
    Smith, Nicole
    Eisenberg, Daniel P.
    Gregory, Michael
    Kohn, Philip
    Grogans, Shannon
    Berman, Karen F.
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 91 - 91
  • [9] Effect of striatal dopaminergic denervation on [18F]FDOPA-, [11C]DTBZ-, and [11C]MP-PET scans: A comparative study in patients with Parkinson's disease
    Lee, CS
    Samii, A
    Sossi, V
    Ruth, TJ
    Schulzer, M
    Calne, DB
    Stoessl, AJ
    NEUROLOGY, 1999, 52 (06) : A175 - A175
  • [10] Reduced uptake on [18F]FDOPA pet imaging in welders with occupational manganese exposure
    Criswell, S. R.
    Perlmutter, J. S.
    Flores, H. P.
    Videen, T. O.
    Moerlein, S. M.
    Racette, B. A.
    MOVEMENT DISORDERS, 2010, 25 (07) : S375 - S376